Drug news
FDA accepts new drug application from Pfizer for tafamidis for TTR-FAP
After a Refusal to File notification from the FDA for tafamidis from Pfizer, the FDA has now accepted the new drug application for Transthyretin Familial Amyloid Polyneuropathy
(TTR-FAP) a rare, progressive fatal neurodegenerative disease, which affects about 8,000 patients worldwide.The drug is approved as Vyndaqel in the EU.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.